1106867-72-4 Usage
General Description
4-Ethoxy-2-formylphenylboronic acid is a chemical compound with the molecular formula C10H11BO4. It is a boronic acid derivative that contains an ethoxy group and a formyl group attached to a phenyl ring. 4-ETHOXY-2-FORMYLPHENYLBORONIC ACID is commonly used in the field of organic chemistry as a building block for the synthesis of various pharmaceuticals, agrochemicals, and materials. 4-Ethoxy-2-formylphenylboronic acid is known for its ability to react with various organic compounds through boron-mediated processes, making it a valuable reagent in the production of functionalized molecules. Additionally, it has been studied for its potential applications in the development of new materials and catalysts due to its unique chemical properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1106867-72-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,0,6,8,6 and 7 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1106867-72:
(9*1)+(8*1)+(7*0)+(6*6)+(5*8)+(4*6)+(3*7)+(2*7)+(1*2)=154
154 % 10 = 4
So 1106867-72-4 is a valid CAS Registry Number.
1106867-72-4Relevant articles and documents
Design and enantioselective synthesis of 3-(α-acrylic acid) benzoxaboroles to combat carbapenemase resistance
Chen, Fener,Chen, Xiao-Pan,Deng, Ji,Li, Gen,Li, Guo-Bo,Schofield, Christopher J.,Xiao, You-Cai,Yan, Yu-Hang,Yu, Jun-Lin,Zhu, Kai-Rong,Brem, Jürgen
supporting information, p. 7709 - 7712 (2021/08/09)
Chiral 3-substituted benzoxaboroles were designed as carbapenemase inhibitors and efficiently synthesisedviaasymmetric Morita-Baylis-Hillman reaction. Some of the benzoxaboroles were potent inhibitors of clinically relevant carbapenemases and restored the activity of meropenem in bacteria harbouring these enzymes. Crystallographic analyses validate the proposed mechanism of binding to carbapenemases,i.e.in a manner relating to their antibiotic substrates. The results illustrate how combining a structure-based design approach with asymmetric catalysis can efficiently lead to potent β-lactamase inhibitors and provide a starting point to develop drugs combatting carbapenemases.
